Shares of Tempus AI Inc. (NASDAQ: TEM) surged 5.04% on November 11, 2024, after the company announced the publication of a significant study highlighting the benefits of using both RNA and DNA sequencing in advanced cancer care.

The study, published in JAMA Network Open, analyzed data from over 5,500 patients with advanced non-small cell lung cancer (NSCLC). The findings revealed that concurrent RNA- and DNA-based next-generation sequencing (NGS) led to the detection of more actionable structural variants compared to DNA sequencing alone.

Specifically, the study found that 8.8% of patients had at least one actionable variant identified by one or both assays, and the concurrent use of RNA and DNA sequencing resulted in a 15.3% increase in identifying patients with actionable variants. Moreover, it more than doubled the detection of emerging, rare structural variants compared to DNA sequencing alone.